Health ❯Obesity

Treatment Options

Medications Pharmaceuticals Weight Loss Drugs GLP-1 Medications Injectable Medications Pharmaceutical Treatments Medication GLP-1 Drugs Weight Loss Injections Drug Combinations

GLP-1 Weight-Loss Drugs Fail to Boost Fitness and Cause Significant Muscle Loss

University of Virginia experts recommend exercise regimens incorporating nutrition supplements to counter GLP-1-induced muscle loss

Hims & Hers Plans Canadian Launch of Generic Semaglutide After Zava Acquisition

Amgen Advances Monthly Obesity Drug to Phase 3 After 20% Weight Loss in Mid-Stage Trial

Bariatric Surgery Surpasses GLP-1 Drugs in Real-World Weight Loss

Former Weight Watchers Leader Nears Weight Goal After Mounjaro Success

Novo Nordisk Revises 2025 Outlook as FDA Crackdown and Competition Reshape Wegovy Market

UK to Trial Pharmacy-Based NHS Weight-Loss Jab Prescriptions

UK Nears One Million Users of Weight-Loss Jabs as New Benefits and Risks Emerge

Pfizer Halts Development of Danuglipron After Liver Safety Concerns

Roche and Zealand Partner in $5.3 Billion Deal for Obesity Drug Development

AbbVie Enters Obesity Drug Market with $2.2 Billion Licensing Deal

Eli Lilly Expands Zepbound Access with New Doses and Lower Prices

Novo Nordisk Reports Doubling Wegovy Sales, Projects Slower Growth in 2025

GLP-1 Drugs Revolutionize Obesity Treatment While Raising Questions About Risks and Costs

Growing Demand for Weight-Loss Drugs in the UK Raises Safety and Accessibility Concerns

Nestle Introduces Protein Shot to Support Weight Loss and Hunger Management

Amgen's Weight-Loss Drug Shows Promise but Faces Investor Skepticism

New Weight Loss Drug Shows Promise Without Nausea

Novo Nordisk Urges FDA to Ban Compounded Versions of Ozempic and Wegovy

FDA Reconsiders Ban on Compounded Versions of Eli Lilly's Weight Loss Drug